Interviews

Luis Torres, MBA, vice president, Managed Care, BioPlus Specialty Pharmacy, discusses the importance of co-pay assistance programs for costly specialty drugs.

Christopher W. Kennedy, MSM, Chief Operating Officer, Heritage Biologics, discusses how data can translate to improvements in patient care.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Ali McBride, PharmD, MS, BCPS, BCOP, explains what strategies can help ensure patients are adherent to oral chemotherapy regimens.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Ray Bailey, BPharm, RPh, Pharmacy Director at Florida Cancer Speciality, discusses interventions aimed at reducing the waste and cost of expensive oral chemotherapy treatments.

Brandon Newman, PharmD, CSP, Program Director, Vanderbilt Specialty Pharmacy, speaks about how specialty pharmacies have to adjust their operations to meet the needs of their patients.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Howard Cohen, RPh, MS, FASHP, from Smilow Cancer Hospital, Yale-New Haven Health, discusses how information technology can be utilized to improve medication adherence on patients with cancer.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Ray Bailey, BPharm, RPh, Pharmacists Director at Florida Cancer Specialists, discusses important considerations for managing oral chemotherapy care plans and improving adherence in patients.

Christopher W. Kennedy, MSM, Chief Operating Officer, Heritage Biologics, speaks about the positive effects telehealth can have on specialty pharmacy patients.

Ron Lanton III, Esq, President, True North Political Solutions, makes predictions about how dealings with biosimilars may change in 2018.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Julianne Orr, PharmD, from the Indiana University Health Simon Cancer Center, discusses how pharmacists can help patients who are transitioning from an infusion product to an oral chemotherapy.

Ron Lanton III, Esq, President, True North Political Solutions, discusses how drug manufacturers have responded to the emergence of biosimilars thus far.

Christopher W. Kennedy, MSM, Chief Operating Officer, Heritage Biologics, discusses how specialty pharmacies can implement value-based reimbursement.

Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, talks about the potential merits of outcomes-based contracting for drugs that treat rare diseases.

Matt Gillin, Chief Executive Officer, Relay Network, speaks about how smartphones are crucial to the patient journey.

In this clip, Angela Yao, a PharmD candidate at the Rutgers University Ernest Mario School of Pharmacy, discusses the first of three qualities that she believes are essential to pharmacy students: mentorship.

Achilles Alon, PharmD, RPh, Director of Specialty Pharmacy, Co-owner of ACE-Rx Specialty Pharmacy, shares complications in treating patients with Crohn's disease.

Kyle Truitt, Co-Founder, Turning Point, LLC, speaks about how pharmaceutical manufacturers can benefit from the launch of the High-Performing Specialty Pharmacy Association.

Ron Lanton III, Esq., President, True North Political Solutions, speaks about proposed legislation that could bolster the emergence of biosimilars.

John Giannouris, vice president, Specialty Pharmacy Services, ValueCentric, speaks about how specialty pharmacies and other stakeholders can harness patient data to improve outcomes.

Brandon Newman, PharmD, CSP, Program Director, Vanderbilt Specialty Pharmacy, speaks to the benefits of becoming a certified specialty pharmacist.

Shiela Arquette, RPh, BS Pharm, Executive Director, National Association of Specialty Pharmacy, discusses how the organization has fought against direct and indirect remuneration fees on behalf of specialty pharmacies.

Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, speaks about the many considerations that have to be addressed when launching a novel rare disease drug in a specialty-naive market.

Mike Agostino, RPh, President, National Association of Specialty Pharmacy, reflects on how the organization advances the specialty pharmacy industry through their annual meeting.

Matt Gillin, Chief Executive Officer, Relay Network, speaks about takeaways specialty pharmacies can learn from other businesses in terms of customer communications, adoption, and behavior change.

Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, speaks to the difficulties that face manufacturers who are launching a novel specialty product.

Christopher W. Kennedy, MSM, Chief Operating Officer, Heritage Biologics, discusses the importance of value-based care for the specialty pharmacy industry.

John Giannouris, vice president, Specialty Pharmacy Services, ValueCentric, discusses the features specialty pharmaceutical manufacturers look for when choosing a data aggregator.

Ron Lanton III, Esq., President, True North Political Solutions, touches on some policies that are changing and may support biosimilar development.